1. Home
  2. ALLO vs UIS Comparison

ALLO vs UIS Comparison

Compare ALLO & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • UIS
  • Stock Information
  • Founded
  • ALLO 2017
  • UIS 1942
  • Country
  • ALLO United States
  • UIS United States
  • Employees
  • ALLO N/A
  • UIS N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • UIS EDP Services
  • Sector
  • ALLO Health Care
  • UIS Technology
  • Exchange
  • ALLO Nasdaq
  • UIS Nasdaq
  • Market Cap
  • ALLO 438.2M
  • UIS 474.3M
  • IPO Year
  • ALLO 2018
  • UIS N/A
  • Fundamental
  • Price
  • ALLO $1.82
  • UIS $6.78
  • Analyst Decision
  • ALLO Strong Buy
  • UIS
  • Analyst Count
  • ALLO 10
  • UIS 0
  • Target Price
  • ALLO $10.06
  • UIS N/A
  • AVG Volume (30 Days)
  • ALLO 3.1M
  • UIS 488.8K
  • Earning Date
  • ALLO 03-13-2025
  • UIS 02-19-2025
  • Dividend Yield
  • ALLO N/A
  • UIS N/A
  • EPS Growth
  • ALLO N/A
  • UIS N/A
  • EPS
  • ALLO N/A
  • UIS N/A
  • Revenue
  • ALLO $43,000.00
  • UIS $2,020,600,000.00
  • Revenue This Year
  • ALLO N/A
  • UIS $0.92
  • Revenue Next Year
  • ALLO N/A
  • UIS $2.90
  • P/E Ratio
  • ALLO N/A
  • UIS N/A
  • Revenue Growth
  • ALLO 26.47
  • UIS 0.29
  • 52 Week Low
  • ALLO $1.78
  • UIS $3.32
  • 52 Week High
  • ALLO $5.78
  • UIS $8.93
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.69
  • UIS 51.41
  • Support Level
  • ALLO $2.11
  • UIS $6.08
  • Resistance Level
  • ALLO $2.10
  • UIS $6.70
  • Average True Range (ATR)
  • ALLO 0.17
  • UIS 0.25
  • MACD
  • ALLO -0.02
  • UIS 0.06
  • Stochastic Oscillator
  • ALLO 5.69
  • UIS 93.33

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides solutions that transform digital workplaces securely and create exceptional end-user experiences. CA&I provides digital platform, applications and infrastructure solutions. ECS provides solutions that harness secure, continuous high-intensity computing and enable digital services through software-defined operating environments.

Share on Social Networks: